1
|
Liang X, Ren H, Han F, Liang R, Zhao J, Liu H. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology. Med Res Rev 2024; 44:632-685. [PMID: 37983964 DOI: 10.1002/med.21992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 06/13/2023] [Accepted: 10/29/2023] [Indexed: 11/22/2023]
Abstract
Imbalances in protein and noncoding RNA levels in vivo lead to the occurrence of many diseases. In addition to the use of small molecule inhibitors and agonists to restore these imbalances, recently emerged targeted degradation technologies provide a new direction for disease treatment. Targeted degradation technology directly degrades target proteins or RNA by utilizing the inherent degradation pathways, thereby eliminating the functions of pathogenic proteins (or RNA) to treat diseases. Compared with traditional therapies, targeted degradation technology which avoids the principle of traditional inhibitor occupation drive, has higher efficiency and selectivity, and widely expands the range of drug targets. It is one of the most promising and hottest areas for future drug development. Herein, we systematically introduced the in vivo degradation systems applied to degrader design: ubiquitin-proteasome system, lysosomal degradation system, and RNA degradation system. We summarized the development progress, structural characteristics, and limitations of novel chimeric design technologies based on different degradation systems. In addition, due to the lack of clear ligand-binding pockets, about 80% of disease-associated proteins cannot be effectively intervened with through traditional therapies. We deeply elucidated how to use targeted degradation technology to discover and design molecules for representative undruggable targets including transcription factors, small GTPases, and phosphatases. Overall, this review provides a comprehensive and systematic overview of targeted degradation technology-related research advances and a new guidance for the chimeric design of undruggable targets.
Collapse
Affiliation(s)
- Xuewu Liang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Hairu Ren
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
| | - Fengyang Han
- School of Pharmacy, Fudan University, Shanghai, China
| | - Renwen Liang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Jiayan Zhao
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
| | - Hong Liu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China
| |
Collapse
|
2
|
Guns J, Vanherle S, Hendriks JJA, Bogie JFJ. Protein Lipidation by Palmitate Controls Macrophage Function. Cells 2022; 11:cells11030565. [PMID: 35159374 PMCID: PMC8834383 DOI: 10.3390/cells11030565] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 02/03/2022] [Accepted: 02/04/2022] [Indexed: 01/27/2023] Open
Abstract
Macrophages are present in all tissues within our body, where they promote tissue homeostasis by responding to microenvironmental triggers, not only through clearance of pathogens and apoptotic cells but also via trophic, regulatory, and repair functions. To accomplish these divergent functions, tremendous dynamic fine-tuning of their physiology is needed. Emerging evidence indicates that S-palmitoylation, a reversible post-translational modification that involves the linkage of the saturated fatty acid palmitate to protein cysteine residues, directs many aspects of macrophage physiology in health and disease. By controlling protein activity, stability, trafficking, and protein–protein interactions, studies identified a key role of S-palmitoylation in endocytosis, inflammatory signaling, chemotaxis, and lysosomal function. Here, we provide an in-depth overview of the impact of S-palmitoylation on these cellular processes in macrophages in health and disease. Findings discussed in this review highlight the therapeutic potential of modulators of S-palmitoylation in immunopathologies, ranging from infectious and chronic inflammatory disorders to metabolic conditions.
Collapse
Affiliation(s)
- Jeroen Guns
- Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium; (J.G.); (S.V.); (J.J.A.H.)
- University MS Center, Hasselt University, 3500 Hasselt, Belgium
| | - Sam Vanherle
- Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium; (J.G.); (S.V.); (J.J.A.H.)
- University MS Center, Hasselt University, 3500 Hasselt, Belgium
| | - Jerome J. A. Hendriks
- Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium; (J.G.); (S.V.); (J.J.A.H.)
- University MS Center, Hasselt University, 3500 Hasselt, Belgium
| | - Jeroen F. J. Bogie
- Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium; (J.G.); (S.V.); (J.J.A.H.)
- University MS Center, Hasselt University, 3500 Hasselt, Belgium
- Correspondence: ; Tel.: +32-1126-9261
| |
Collapse
|
3
|
Miller JJ, Bohnsack RN, Olson LJ, Ishihara M, Aoki K, Tiemeyer M, Dahms NM. Tissue plasminogen activator is a ligand of cation-independent mannose 6-phosphate receptor and consists of glycoforms that contain mannose 6-phosphate. Sci Rep 2021; 11:8213. [PMID: 33859256 PMCID: PMC8050316 DOI: 10.1038/s41598-021-87579-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 03/30/2021] [Indexed: 01/18/2023] Open
Abstract
Plasmin is the key enzyme in fibrinolysis. Upon interaction with plasminogen activators, the zymogen plasminogen is converted to active plasmin. Some studies indicate plasminogen activation is regulated by cation-independent mannose 6-phosphate receptor (CI-MPR), a protein that facilitates lysosomal enzyme trafficking and insulin-like growth factor 2 downregulation. Plasminogen regulation may be accomplished by CI-MPR binding to plasminogen or urokinase plasminogen activator receptor. We asked whether other members of the plasminogen activation system, such as tissue plasminogen activator (tPA), also interact with CI-MPR. Because tPA is a glycoprotein with three N-linked glycosylation sites, we hypothesized that tPA contains mannose 6-phosphate (M6P) and binds CI-MPR in a M6P-dependent manner. Using surface plasmon resonance, we found that two sources of tPA bound the extracellular region of human and bovine CI-MPR with low-mid nanomolar affinities. Binding was partially inhibited with phosphatase treatment or M6P. Subsequent studies revealed that the five N-terminal domains of CI-MPR were sufficient for tPA binding, and this interaction was also partially mediated by M6P. The three glycosylation sites of tPA were analyzed by mass spectrometry, and glycoforms containing M6P and M6P-N-acetylglucosamine were identified at position N448 of tPA. In summary, we found that tPA contains M6P and is a CI-MPR ligand.
Collapse
Affiliation(s)
- James J Miller
- Department of Biochemistry, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA
| | - Richard N Bohnsack
- Department of Biochemistry, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA
| | - Linda J Olson
- Department of Biochemistry, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA
| | - Mayumi Ishihara
- Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Rd, Athens, GA, 30602, USA
| | - Kazuhiro Aoki
- Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Rd, Athens, GA, 30602, USA
| | - Michael Tiemeyer
- Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Rd, Athens, GA, 30602, USA.
| | - Nancy M Dahms
- Department of Biochemistry, Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA.
| |
Collapse
|
4
|
PRODUCTION AND APPLICATION OF ANGIOSTATINS FOR THE TREATMENT OF OCULAR NEOVASCULAR DISEASES. BIOTECHNOLOGIA ACTA 2021. [DOI: 10.15407/biotech14.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Angiostatins comprise a group of kringle-containing proteolytically-derived fragments of plasminogen/plasmin, which act as potent inhibitory mediators of endothelial cells proliferation and migration. Angiostatins are involved in modulation of vessel growth in healthy tissues and various pathological conditions associated with aberrant neovascularization. The aim of the present paper was to summarize available information, including our own experimental data, on prospects of angiostatin application for treatment of ocular neovascular diseases (OND), focusing on retinal pathologies and corneal injury. In particular, literature data on prospective and retrospective studies, clinical trials and animal models relating to the pathophysiology, investigation and management of OND are described. Special emphasis was made on the laboratory approaches of production of different angiostatin isoforms, as well as comparison of antiangiogenic capacities of native and recombinant angiostatin polypeptides. Several studies reported that angiostatins may completely abolish pathologic angiogenesis in diabetic proliferative retinopathy without affecting normal retinal vessel development and without exhibiting adverse side effects. Angiostatins have been tested as a tool for corneal antiangiogenesis target therapy in order to manage diverse ocular surface pathological conditions induced by traumas, chemical burns, previous surgery, chronic contact lens wear, autoimmune diseases, keratitis and viral infections (herpes, COVID-19), corneal graft rejection, etc. Among all known angiostatin species, isolated K5 plasminogen fragment was shown to display the most potent inhibitory activity against proliferation of endothelial cells via triggering multiple signaling pathways, which lead to cell death and resulting angiogenesis suppression. Application of adenoviral genetic construct encoding angiostatin K5 as a promising tool for OND treatment illustrates a vivid example of upcoming revolution in local gene therapy. Further comprehensive studies are necessary to elucidate the clinical potential and optimal regimes of angiostatinbased intervention modalities for treating ocular neovascularization.
Collapse
|
5
|
Aguayo-Ortiz R, Meza-Cervantez P, Castillo R, Hernández-Campos A, Dominguez L, Yépez-Mulia L. Insights into the Giardia intestinalis enolase and human plasminogen interaction. MOLECULAR BIOSYSTEMS 2018; 13:2015-2023. [PMID: 28770921 DOI: 10.1039/c7mb00252a] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Giardia intestinalis is an intestinal parasite that causes diarrhea in humans and animals worldwide. The enolase of G. intestinalis (GiENO) participates in its glycolysis pathway and is abundantly expressed in the parasite cytosol; however, its localization on the surface of trophozoites and cysts has been demonstrated. Enolases from bacteria and parasites can have different functions and are considered moonlighting proteins, for example, as a cell surface plasminogen receptor. In relation to GiENO, no studies have been performed about its possible participation as a plasminogen receptor. In this work, we employed molecular docking and multiscale molecular dynamics (MD) simulations to explore the possible interactions of human plasminogen (HsPLG) with the open and closed GiENO conformations. Our proposed GiENO plasminogen binding site (PLGBs) was identified at Lys266 based on the sequence comparison with bacterial enolase known to act as a plasminogen receptor. Our docking results performed with multiple MD snapshots of the closed GiENO conformation showed that Lys266 preferentially binds to the K5 domain of HsPLG. On the other hand, open GiENO conformations from all-atom and coarse-grained simulations indicated a high preference of the HsPLG K4 domain for lysine residues 186 and 188. Furthermore, we identified a potential N-glycosylation site of GiENO which suggests a possible explanation for the parasite cell surface localization or host mucin oligosaccharide adhesion mechanism. Our study constitutes the first multiscale computational study to explore the plasminogen receptor function of GiENO for its further consideration as a potential therapeutic target for giardiasis treatment.
Collapse
Affiliation(s)
- R Aguayo-Ortiz
- Facultad de Química, Departamento de Fisicoquímica, Universidad Nacional Autónoma de México, CDMX, México 04510, Mexico.
| | | | | | | | | | | |
Collapse
|
6
|
Lin KH, Kuo CH, Kuo WW, Ho TJ, Pai P, Chen WK, Pan LF, Wang CC, Padma VV, Huang CY. NFIL3 suppresses hypoxia-induced apoptotic cell death by targeting the insulin-like growth factor 2 receptor. J Cell Biochem 2016; 116:1113-20. [PMID: 25536374 DOI: 10.1002/jcb.25067] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Revised: 12/14/2014] [Accepted: 12/18/2014] [Indexed: 11/08/2022]
Abstract
The insulin-like growth factor-II/mannose 6-phosphate receptor (IGF2R) over-expression correlates with heart disease progression. The IGF2R is not only an IGF2 clearance receptor, but it also triggers signal transduction, resulting in cardiac hypertrophy, apoptosis and fibrosis. The present study investigated the nuclear factor IL-3 (NFIL3), a transcription factor of the basic leucine zipper superfamily, and its potential pro-survival effects in cardiomyocytes. NFIL3 might play a key role in heart development and act as a survival factor in the heart, but the regulatory mechanisms are still unclear. IGF2 and IGF2R protein expression were highly increased in rat hearts subjected to hemorrhagic shock. IGF2R protein expression was also up-regulated in H9c2 cells exposed to hypoxia. Over-expression of NFIL3 in H9c2 cardiomyoblast cells inhibited the induction of hypoxia-induced apoptosis and down-regulated IGF2R expression levels. Gel shift assay, double-stranded DNA pull-down assay and chromatin immune-precipitation analyses indicated that NFIL3 binds directly to the IGF2R promoter region. Using a luciferase assay, we further observed NFIL3 repress IGF2R gene promoter activity. Our results demonstrate that NFIL3 is an important negative transcription factor, which through binding to the promoter of IGF2R, suppresses the apoptosis induced by IGF2R signaling in H9c2 cardiomyoblast cells under hypoxic conditions.
Collapse
Affiliation(s)
- Kuan-Ho Lin
- Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, 40402, Taiwan; Department of Emergency Medicine, China Medical University Hospital, Taichung, Taiwan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Chen WK, Kuo WW, Hsieh DJY, Chang HN, Pai PY, Lin KH, Pan LF, Ho TJ, Viswanadha VP, Huang CY. CREB Negatively Regulates IGF2R Gene Expression and Downstream Pathways to Inhibit Hypoxia-Induced H9c2 Cardiomyoblast Cell Death. Int J Mol Sci 2015; 16:27921-30. [PMID: 26610485 PMCID: PMC4661925 DOI: 10.3390/ijms161126067] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 10/23/2015] [Indexed: 01/18/2023] Open
Abstract
During hypoxia, gene expression is altered by various transcription factors. Insulin-like growth factor-II (IGF2) is known to be induced by hypoxia, which binds to IGF2 receptor IGF2R that acts like a G protein-coupled receptor, might cause pathological hypertrophy or activation of the mitochondria-mediated apoptosis pathway. Cyclic adenosine monophosphate (cAMP) responsive element-binding protein (CREB) is central to second messenger-regulated transcription and plays a critical role in the cardiomyocyte survival pathway. In this study, we found that IGF2R level was enhanced in H9c2 cardiomyoblasts exposed to hypoxia in a time-dependent manner but was down-regulated by CREB expression. The over-expression of CREB in H9c2 cardiomyoblasts suppressed the induction of hypoxia-induced IGF2R expression levels and reduced cell apoptosis. Gel shift assay results further indicated that CREB binds to the promoter sequence of IGF2R. With a luciferase assay method, we further observed that CREB represses IGF2R promoter activity. These results suggest that CREB plays an important role in the inhibition of IGF2R expression by binding to the IGF2R promoter and further suppresses H9c2 cardiomyoblast cell apoptosis induced by IGF2R signaling under hypoxic conditions.
Collapse
Affiliation(s)
- Wei-Kung Chen
- Department of Emergency Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
| | - Wei-Wen Kuo
- Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan.
| | - Dennis Jine-Yuan Hsieh
- School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 40201, Taiwan.
| | - Hsin-Nung Chang
- Graduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan.
| | - Pei-Ying Pai
- Division of Cardiology, China Medical University Hospital, Taichung 40402, Taiwan.
| | - Kuan-Ho Lin
- Department of Emergency Medicine, China Medical University Hospital, Taichung 40402, Taiwan.
- Graduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan.
- College of Medicine, China Medical University, Taichung 40402, Taiwan.
| | - Lung-Fa Pan
- Cardiology Department, Taichung Armed Forces General Hospital. Taichung 41152, Taiwan.
- Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 40601, Taiwan.
| | - Tsung-Jung Ho
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
- Chinese Medicine Department, China Medical University Beigang Hospital, Yunlin 651, Taiwan.
| | | | - Chih-Yang Huang
- Chinese Medicine Department, China Medical University Beigang Hospital, Yunlin 651, Taiwan.
- Graduate Institute of Basic Medical Science, China Medical University, Taichung 40402, Taiwan.
- Department of Health and Nutrition Biotechnology, Asia University, Taichung 41354, Taiwan.
| |
Collapse
|
8
|
Olson LJ, Castonguay AC, Lasanajak Y, Peterson FC, Cummings RD, Smith DF, Dahms NM. Identification of a fourth mannose 6-phosphate binding site in the cation-independent mannose 6-phosphate receptor. Glycobiology 2015; 25:591-606. [PMID: 25573276 DOI: 10.1093/glycob/cwv001] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 01/05/2015] [Indexed: 11/12/2022] Open
Abstract
The 300 kDa cation-independent mannose 6-phosphate receptor (CI-MPR) plays an essential role in lysosome biogenesis by targeting ∼ 60 different phosphomannosyl-containing acid hydrolases to the lysosome. This type I membrane glycoprotein has a large extracellular region comprised of 15 homologous domains. Two mannose 6-phosphate (M6P) binding sites have been mapped to domains 3 and 9, whereas domain 5 binds preferentially to the phosphodiester, M6P-N-acetylglucosamine (GlcNAc). A structure-based sequence alignment predicts that the C-terminal domain 15 contains three out of the four conserved residues identified as essential for carbohydrate recognition by domains 3, 5 and 9 of the CI-MPR, but lacks two cysteine residues that are predicted to form a disulfide bond. To determine whether domain 15 of the CI-MPR has lectin activity and to probe its carbohydrate-binding specificity, truncated forms of the CI-MPR were tested for binding to acid hydrolases with defined N-glycans in surface plasmon resonance analyses, and used to interrogate a phosphorylated glycan microarray. The results show that a construct encoding domains 14-15 binds both M6P and M6P-GlcNAc with similar affinity (Kd = 13 and 17 μM, respectively). Site-directed mutagenesis studies demonstrate the essential role of the conserved Tyr residue in domain 15 for phosphomannosyl binding. A structural model of domain 15 was generated that predicted an Arg residue to be in the binding pocket and mutagenesis studies confirmed its important role in carbohydrate binding. Together, these results show that the CI-MPR contains a fourth carbohydrate-recognition site capable of binding both phosphomonoesters and phosphodiesters.
Collapse
Affiliation(s)
- Linda J Olson
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Alicia C Castonguay
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Yi Lasanajak
- National Center for Functional Glycomics, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Francis C Peterson
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Richard D Cummings
- National Center for Functional Glycomics, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - David F Smith
- National Center for Functional Glycomics, Emory University School of Medicine, Atlanta, GA 30322, USA
| | - Nancy M Dahms
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| |
Collapse
|
9
|
Bohnsack RN, Warejcka DJ, Wang L, Gillespie SR, Bernstein AM, Twining SS, Dahms NM. Expression of insulin-like growth factor 2 receptor in corneal keratocytes during differentiation and in response to wound healing. Invest Ophthalmol Vis Sci 2014; 55:7697-708. [PMID: 25358730 DOI: 10.1167/iovs.14-15179] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
PURPOSE Insulin-like growth factor 2 receptor (IGF2R) associates with ligands that influence wound healing outcomes. However, the expression pattern of IGF2R and its role in the cornea is unknown. METHODS Human keratocytes were isolated from donor corneas. Fibroblasts (fibroblast growth factor 2 [FGF2]-treated) or myofibroblasts (TGF-β1-treated) were analyzed for IGF2R and α-smooth muscle actin (α-SMA) expression by Western blotting and immunolocalization. Mouse corneas were wounded in vivo and porcine corneas ex vivo. The IGF2R and α-SMA protein expression were visualized and quantified by immunohistochemistry. The IGF2R gene expression in human corneal fibroblasts was knocked-down with targeted lentiviral shRNA. RESULTS The IGF2R is expressed in epithelial and stromal cells of normal human, mouse, and porcine corneas. The IGF2R increases (11.2 ± 0.4-fold) in the epithelial and (11.7 ± 0.9-fold) stromal layers of in vivo wounded mouse corneas. Double-staining with α-SMA- and IGF2R-specific antibodies reveals that IGF2R protein expression is increased in stromal myofibroblasts in the wounded cornea relative to keratocytes in the normal cornea (11.2 ± 0.8-fold). Human primary stromal keratocytes incubated with FGF2 or TGF-β1 in vitro demonstrate increased expression (2.0 ± 0.4-fold) of IGF2R in myofibroblasts relative to fibroblasts. Conversion of IGF2R shRNA-lentiviral particle transduced corneal fibroblasts to myofibroblasts reveals a dependence on IGF2R expression, as only 40% ± 10% of cells transduced converted to myofibroblasts compared to 86% ± 3% in control cells. CONCLUSIONS The IGF2R protein expression is increased during corneal wound healing and IGF2R regulates human corneal fibroblast to myofibroblast differentiation.
Collapse
Affiliation(s)
- Richard N Bohnsack
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
| | - Debra J Warejcka
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
| | - Lingyan Wang
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
| | | | - Audrey M Bernstein
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
| | - Sally S Twining
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
| | - Nancy M Dahms
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
| |
Collapse
|
10
|
Leksa V, Pfisterer K, Ondrovičová G, Binder B, Lakatošová S, Donner C, Schiller HB, Zwirzitz A, Mrvová K, Pevala V, Kutejová E, Stockinger H. Dissecting mannose 6-phosphate-insulin-like growth factor 2 receptor complexes that control activation and uptake of plasminogen in cells. J Biol Chem 2012; 287:22450-62. [PMID: 22613725 DOI: 10.1074/jbc.m112.339663] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The plasminogen (Plg) activation cascade on the cell surface plays a central role in cell migration and is involved in a plethora of physiological and pathological processes. Its regulation is coordinated by many receptors, in particular the urokinase-type plasminogen activator receptor (uPAR, CD87), receptors that physically interact and functionally cooperate with uPAR, and Plg binding molecules. Here we studied the impact of one of the Plg binding molecules, the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P-IGF2R, CD222), on cellular Plg activation. By developing both in vitro and in vivo Plg activation assays on size-fractionated lysates of M6P-IGF2R-silenced cells, we identified Plg-associated complexes with M6P-IGF2R as the regulatory factor. Using lipid raft preserving versus dissolving detergents, we found lipid dependence of the Plg regulatory function of these complexes. Furthermore, M6P-IGF2R-silencing in uPAR-positive human cell lines reduced internalization of Plg, resulting in elevated Plg activation. In contrast, the expression of human M6P-IGF2R in mouse embryonic fibroblasts derived from M6P-IGF2R knock-out mice enhanced Plg internalization. Finally, peptide 18-36 derived from the Plg-binding site within M6P-IGF2R enhanced Plg uptake. Thus, by targeting Plg to endocytic pathways, M6P-IGF2R appears to control Plg activation within cells that might be important to restrict plasmin activity to specific sites and substrates.
Collapse
Affiliation(s)
- Vladimir Leksa
- Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, A-1090 Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Castonguay AC, Olson LJ, Dahms NM. Mannose 6-phosphate receptor homology (MRH) domain-containing lectins in the secretory pathway. Biochim Biophys Acta Gen Subj 2011; 1810:815-26. [PMID: 21723917 DOI: 10.1016/j.bbagen.2011.06.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2011] [Revised: 06/13/2011] [Accepted: 06/15/2011] [Indexed: 12/22/2022]
Abstract
BACKGROUND The mannose 6-phosphate receptor homology (MRH) domain-containing family of proteins, which include recycling receptors (mannose 6-phosphate receptors, MPRs), resident endoplasmic reticulum (ER) proteins (glucosidase II β-subunit, XTP3-B, OS-9), and a Golgi glycosyltransferase (GlcNAc-phosphotransferase γ-subunit), are characterized by the presence of one or more MRH domains. Many MRH domains act as lectins and bind specific phosphorylated (MPRs) or non-phosphorylated (glucosidase II β-subunit, XTP3-B and OS-9) high mannose-type N-glycans. The MPRs are the only proteins known to bind mannose 6-phosphate (Man-6-P) residues via their MRH domains. SCOPE OF REVIEW Recent biochemical and structural studies that have provided valuable insight into the glycan specificity and mechanisms of carbohydrate recognition by this diverse group of MRH domain-containing proteins are highlighted. MAJOR CONCLUSIONS Currently, three-dimensional structures are known for ten MRH domains, revealing the conservation of a similar fold. OS-9 and the MPRs use the same four residues (Gln, Arg, Glu, and Tyr) to bind mannose. GENERAL SIGNIFICANCE The MRH domain-containing proteins play key roles in the secretory pathway: glucosidase II, XTP3-B, and OS-9 are involved in the recognition of nascent glycoproteins, whereas the MPRs play an essential role in lysosome biogenesis by targeting Man-6-P-containing lysosomal enzymes to the lysosome.
Collapse
Affiliation(s)
- Alicia C Castonguay
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | | | | |
Collapse
|
12
|
Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, Soler-Cardona A, Ondrovičová G, Kutejová E, Steinhuber E, Breuss J, Drach J, Petzelbauer P, Binder BR, Stockinger H. Soluble M6P/IGF2R Released by TACE Controls Angiogenesis via Blocking Plasminogen Activation. Circ Res 2011; 108:676-85. [DOI: 10.1161/circresaha.110.234732] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Rationale:
The urokinase plasminogen activator (uPA) system is among the most crucial pericellular proteolytic systems associated with the processes of angiogenesis. We previously identified an important regulator of the uPA system in the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R).
Objective:
Here, we wanted to clarify whether and how did the soluble form of M6P/IGF2R (sM6P/IGF2R) contribute to modulation of the uPA system.
Methods and Results:
By using specific inhibitors and RNA interference, we show that the tumor necrosis factor α convertase (TACE, ADAM-17) mediates the release of the ectodomain of M6P/IGF2R from human endothelial cells. We demonstrate further that sM6P/IGF2R binds plasminogen (Plg) and thereby prevents Plg from binding to the cell surface and uPA, ultimately inhibiting in this manner Plg activation. Furthermore, peptide 18-36 derived from the Plg-binding site of M6P/IGF2R mimics sM6P/IGF2R in the inhibition of Plg activation and blocks cancer cell invasion in vitro, endothelial cell invasion in vivo, and tumor growth in vivo.
Conclusions:
The interaction of sM6P/IGF2R with Plg may be an important regulatory mechanism to inhibit migration of cells using the uPA/uPAR system.
Collapse
Affiliation(s)
- Vladimir Leksa
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Robert Loewe
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Brigitte Binder
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Herbert B. Schiller
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Paul Eckerstorfer
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Florian Forster
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Ana Soler-Cardona
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Gabriela Ondrovičová
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Eva Kutejová
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Eva Steinhuber
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Johannes Breuss
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Johannes Drach
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Peter Petzelbauer
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Bernd R. Binder
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| | - Hannes Stockinger
- From the Molecular Immunology Unit (V.L., B.B., H.B.S., P.E., F.F., E.S., H.S.), Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria; Institute of Molecular Biology (V.L., G.O., E.K.), Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Dermatology (R.L., A.S.-C., P.B.), Medical University of Vienna, Austria; Department of Vascular Biology and Thrombosis Research (J.B., B.R.B.), Center for
| |
Collapse
|